Ionis Pharmaceuticals, Inc. · Transaction Mar 6, 2023 · Filed Apr 17, 2023 · $1,001 to $15,000
XNAS · IONS
-0.89% · -$0.3900 · Vol 2.3M
Market closed · last close 4:00 PM ET · price as of 17:33:51 ET
Ionis Pharmaceuticals, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
$43.61
Follow $IONS
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $IONS by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredFri Oct 2 · market closed · Markets closed · resumes Mon 9:30 ET · IONS
MethodologyIONS
Ionis Pharmaceuticals, Inc. Common Stock
Fri Oct 2 · market closed · Markets closed · resumes Mon 9:30 ET
Lower range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
30/ 100
Veridion Score
Lower range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Fri Oct 2 · market closed · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is IONS moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Ionis Pharmaceuticals, Inc. Common Stock
PHARMACEUTICAL PREPARATIONSListed since
1991
Employees
1K
Country
US
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$44.17
Day high
$44.17
Day low
$43.24
Previous close
$44.00
52W high
$86.50
-49.58% from high
52W low
$43.24
1% of range
Market cap
$7.3B
EPS
$-1.3500
Beta
-0.07
Shares out
166.2M
Volume
2.3M
0.61× rel vol
Avg volume
3.8M
VWAP
$43.54
Price history computed in-house
1W
-2.00%
1M
-24.98%
3M
-46.69%
1Y
-36.93%
YTD
-44.87%
SMA 50 $53.91 · below
SMA 200 $70.39 · below
52W position 1%
IONS overview
Related filings and maps
Public disclosures
Congress activity in IONS
Official filing ↗
Ionis Pharmaceuticals, Inc. · Transaction Nov 2, 2016 · Filed Dec 2, 2016 · $15,001 to $50,000
Ionis Pharmaceuticals, Inc. · Transaction Nov 2, 2016 · Filed Dec 2, 2016 · $1,001 to $15,000
Ionis Pharmaceuticals, Inc. · Transaction Nov 2, 2016 · Filed Dec 2, 2016 · $1,001 to $15,000
Ionis Pharmaceuticals, Inc. · Transaction Feb 24, 2016 · Filed Mar 3, 2016 · $1,001 to $15,000
Federal contracts
IONS contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IONS in this window.
Lobbying spend
IONS lobbying filings, year to date.
Registered lobbying filings matched to Ionis Pharmaceuticals, Inc. Common Stock.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IONS in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for IONS.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.